About Synpromics
Synpromics is a company based in Edinburgh (United Kingdom) founded in 2010 was acquired by AskBio in August 2019. Synpromics has raised $9.86 million across 3 funding rounds from investors including AskBio, Scottish Enterprise and Calculus Capital. The company has 46 employees as of December 31, 2021. Synpromics operates in a competitive market with competitors including Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 46 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synpromics Ltd
- Date of Incorporation 27 Aug, 2010
- Jurisdiction MIDLOTHIAN, SCOTLAND
-
Annual Revenue
$125.77 K (USD)-94as on Dec 31, 2020
-
Net Profit
-$4.83 M (USD)-119as on Dec 31, 2020
-
EBITDA
Not available
-
Total Equity Funding
$9.86 M (USD)
in 3 rounds
-
Latest Funding Round
$2.43 M (USD), Grant
Jun 01, 2018
-
Investors
AskBio
& 2 more
-
Employee Count
46
as on Dec 31, 2021
-
Acquired by
AskBio
(Aug 13, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Synpromics
Synpromics has successfully raised a total of $9.86M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $2.43 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Synpromics
Synpromics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include AskBio, Scottish Enterprise and Calculus Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UK venture capital investments are managed by Calculus Capital.
|
Locked | Locked | Locked | |
|
Business development and leadership training programs are offered to companies.
|
Locked | Locked | Locked | |
|
Gene and protein therapies are developed for treating various diseases.
|
Locked | Locked | Locked |
Investor details for Synpromics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synpromics
Investment portfolio details for Synpromics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Synpromics
Detailed financials for Synpromics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synpromics Comparisons
Peer comparison for Synpromics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synpromics
Synpromics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
Detailed competitors of Synpromics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synpromics
Complete news archive for Synpromics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synpromics
Synpromics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Synpromics is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Synpromics is a funded company, having raised a total of $9.86M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Synpromics is 46.
Annual revenue of Synpromics is $125.77K as on Dec 31, 2020.
Synpromics was founded in 2010 in Edinburgh, United Kingdom, within the biotechnology sector. Synthetic promoters are developed to enable precise gene expression control. These are screened through a platform to build a library optimized for the CHO system. Applications include cell and gene therapy, biologics bioprocessing, industrial biotechnology, agricultural biotechnology, and cell-based assays. Operations focus on patentable designs for targeted regulatory solutions.
Synpromics's top competitors include Syngenta, Sutro Biopharma and Avidity Biosciences.
Synpromics has 3 investors. Key investors include AskBio, Scottish Enterprise, and Calculus Capital.